Shots:

• The companies signed an agreement with to evaluate VIR-7832 vs PBO in P-Ib/IIa AGILE study in patients with mild to mod. COVID-19. The trial is expected to be initiated in Q1’21 across up to five sites in the UK
• The preclinical data demonstrated that VIR-7832 enhanced ability to clear infected cells and enhance virus-specific T cell function- treating or prevent COVID-19 infection
• VIR-7832 is a dual-action mAb- currently being evaluated in two global P-III studies for the early treatment of COVID-19 in patients who are at high risk of hospitalization- and for hospitalized patients with COVID-19

 ­ Ref: GSK | Image: GSK